Paul R. Fonteyne
CIK 1727550 · last filed 2026-08-03
Paul R. Fonteyne is a corporate insider who has filed 27 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing, for APMD, was dated Aug 3, 2026. Across all open-market trades the lifetime net is +$350.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $104.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APLS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
501 BOYLSTON STREET SUITE 6102
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APMD | Director | — | $17.76 | — | $0 | 1 | 2026-08-03 |
| AMLX | Director | 3,947 | $26.34 | $104.0K | $75.0K | 6 | 2026-06-08 |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Director | 0 | $41.03 | $0 | $159.0K | 9 | 2026-05-14 |
| COVETRUS, INC. (CVET) Delisted | Director | 0 | $20.99 | $0 | $116.2K | 5 | 2022-10-13 |
| GELESIS HOLDINGS, INC. (GLS.WS) Delisted | Director | 53,832 | $0.01 | $447 | $0 | 1 | 2022-05-09 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Director | 0 | — | — | $0 | 3 | 2020-11-17 |
| Adicet Bio, Inc. (TORC) Delisted | Director | — | — | — | $0 | 2 | 2020-06-05 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-03 | APMD | Mixed | — | $0 | EDGAR |
| 2026-06-08 | AMLX | Grant (A) | — | $0 | EDGAR |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −54,854 | $0 | EDGAR |
| 2026-01-05 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +7,961 | $0 | EDGAR |
| 2025-06-09 | AMLX | Grant (A) | — | $0 | EDGAR |
| 2025-01-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +6,267 | $0 | EDGAR |
| 2024-06-07 | AMLX | Grant (A) | — | $0 | EDGAR |
| 2024-01-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +3,341 | $0 | EDGAR |
| 2023-06-12 | AMLX | Grant (A) | — | $0 | EDGAR |
| 2023-01-04 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +3,867 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.